These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 18584585)

  • 1. Systemic and local effects of angiotensin II blockade in experimental diabetic nephropathy.
    Vieitez P; Gómez O; Uceda ER; Vera ME; Molina-Holgado E
    J Renin Angiotensin Aldosterone Syst; 2008 Jun; 9(2):96-102. PubMed ID: 18584585
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Influence of irbesartan on renal hypertrophy and thickening of glomerular basement-membrane in streptozotocin-induced diabetic rats].
    Liu BC; Luo DD; Sun J; Ma KL; Ruan XZ
    Zhonghua Nei Ke Za Zhi; 2003 May; 42(5):320-3. PubMed ID: 12882713
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effects of angiotensin-II receptor blockers on podocyte damage and glomerular apoptosis in a rat model of experimental streptozotocin-induced diabetic nephropathy.
    Tunçdemir M; Oztürk M
    Acta Histochem; 2011 Dec; 113(8):826-32. PubMed ID: 21269661
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Renin-angiotensin system blockade prevents the increase in plasma transforming growth factor beta 1, and reduces proteinuria and kidney hypertrophy in the streptozotocin-diabetic rat.
    Erman A; Veksler S; Gafter U; Boner G; Wittenberg C; van Dijk DJ
    J Renin Angiotensin Aldosterone Syst; 2004 Sep; 5(3):146-51. PubMed ID: 15526251
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Renin-angiotensin blockade lowers MCP-1 expression in diabetic rats.
    Kato S; Luyckx VA; Ots M; Lee KW; Ziai F; Troy JL; Brenner BM; MacKenzie HS
    Kidney Int; 1999 Sep; 56(3):1037-48. PubMed ID: 10469372
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of blocking the renin-angiotensin system on expression and translocation of protein kinase C isoforms in the kidney of diabetic rats.
    Zhang L; Ma J; Gu Y; Lin S
    Nephron Exp Nephrol; 2006; 104(3):e103-11. PubMed ID: 16837815
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ACE inhibition and AT1 receptor blockade prevent fatty liver and fibrosis in obese Zucker rats.
    Toblli JE; Muñoz MC; Cao G; Mella J; Pereyra L; Mastai R
    Obesity (Silver Spring); 2008 Apr; 16(4):770-6. PubMed ID: 18239590
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Angiotensin II receptor blocker attenuates overexpression of vascular endothelial growth factor in diabetic podocytes.
    Lee EY; Shim MS; Kim MJ; Hong SY; Shin YG; Chung CH
    Exp Mol Med; 2004 Feb; 36(1):65-70. PubMed ID: 15031673
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effects of dual blockade of the renin-angiotensin system on urinary protein and transforming growth factor-beta excretion in 2 groups of patients with IgA and diabetic nephropathy.
    Song JH; Lee SW; Suh JH; Kim ES; Hong SB; Kim KA; Kim MJ
    Clin Nephrol; 2003 Nov; 60(5):318-26. PubMed ID: 14640237
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Local delivery of angiotensin II receptor blockers into the kidney passively attenuates inflammatory reactions during the early phases of streptozotocin-induced diabetic nephropathy through inhibition of calpain activity.
    Kamal F; Yanakieva-Georgieva N; Piao H; Morioka T; Oite T
    Nephron Exp Nephrol; 2010; 115(3):e69-79. PubMed ID: 20424485
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Angiotensin II type I receptor blockade suppresses glomerular renin-angiotensin system activation, oxidative stress, and progressive glomerular injury in rat anti-glomerular basement membrane glomerulonephritis.
    Kinoshita Y; Kondo S; Urushihara M; Suga K; Matsuura S; Takamatsu M; Shimizu M; Nishiyama A; Kawachi H; Kagami S
    Transl Res; 2011 Oct; 158(4):235-48. PubMed ID: 21925120
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Renal protective effect of angiotensin II receptor antagonist on growth hormone-treated nephrotic rats].
    Li S; Cao B; Feng QH; Li XZ
    Zhonghua Er Ke Za Zhi; 2003 Nov; 41(11):817-21. PubMed ID: 14728886
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Irbesartan ameliorates diabetic nephropathy by reducing the expression of connective tissue growth factor and alpha-smooth-muscle actin in the tubulointerstitium of diabetic rats.
    Ren X; Guan G; Liu G; Liu G
    Pharmacology; 2009; 83(2):80-7. PubMed ID: 19065061
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of angiotensin-converting enzyme inhibition and angiotensin II type 1 receptor blockade on streptozotocin-induced diabetic nephropathy.
    Sen S; Kanter M; Ustundag S; Aktas C; Dogutan H; Yalcin O
    Ren Fail; 2008; 30(10):1023-33. PubMed ID: 19016156
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Regulation of the Ku70 and apoptosis-related proteins in experimental diabetic nephropathy.
    Tunçdemir M; Öztürk M
    Metabolism; 2016 Oct; 65(10):1466-77. PubMed ID: 27621182
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of candesartan, an angiotensin II type 1 receptor blocker, on diabetic nephropathy in KK/Ta mice.
    Liao J; Kobayashi M; Kanamuru Y; Nakamura S; Makita Y; Funabiki K; Horikoshi S; Tomino Y
    J Nephrol; 2003; 16(6):841-9. PubMed ID: 14736011
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of dual blockade of the renin angiotensin system in hypertensive type 2 diabetic patients with nephropathy.
    Matos JP; de Lourdes Rodrigues M; Ismerim VL; Boasquevisque EM; Genelhu V; Francischetti EA
    Clin Nephrol; 2005 Sep; 64(3):180-9. PubMed ID: 16175942
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of irbesartan on the antioxidant defence system and nitric oxide release in diabetic rat kidney.
    Anjaneyulu M; Chopra K
    Am J Nephrol; 2004; 24(5):488-96. PubMed ID: 15353911
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mechanisms of irbesartan in prevention of renal lesion in streptozotocin-induced diabetic rats.
    Liu BC; Chen Q; Luo DD; Sun J; Phillips AO; Ruan XZ; Liu NF
    Acta Pharmacol Sin; 2003 Jan; 24(1):67-73. PubMed ID: 12511232
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CS-886, a new angiotensin II type 1 receptor antagonist, ameliorates glomerular anionic site loss and prevents progression of diabetic nephropathy in Otsuka Long-Evans Tokushima fatty rats.
    Koga K; Yamagishi S; Takeuchi M; Inagaki Y; Amano S; Okamoto T; Saga T; Makita Z; Yoshizuka M
    Mol Med; 2002 Oct; 8(10):591-9. PubMed ID: 12477969
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.